We generate iPSC-derived, multi-cellular and lineage-controlled 3D cardiac tissue models from healthy donors or patients that recapitulate the physiology of the human heart in a way not seen before with conventional 2D or bioengineered model systems.
The Cardioid technology was invented by the research group of Sasha Mendjan at the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), one of the global leaders in stem cell and organoid research.
For more information on the technology please refer to the scientific publications in the News & Media section.
We are developing an automated, highly scalable Cardioid generation, acquisition and quality control system coupled with AI capabilities enabling drug screening with a complex 3D biology at unprecedented throughput and reproducibility and at a cost comparable with conventional cell-based in vitro models.
We are developing new, scalable and physiologically unique disease models to tackle drug-induced and genetic cardiomyopathies as well as myocardial infarction and its ensuing fibrosis, indications with few treatment options and a desperate need for therapeutic innovations.
We are developing a powerful, predictive high throughput screening platform for cardiotoxicity testing and cardiac drug discovery by combining innovative hardware solutions of our technology partner Molecular Devices with complex 3D heart tissue models, relevant functional assays and high-content read-outs as well as AI-based big data analysis software.
If you want to know more of the cardioid technology you can submit a message below or refer to the additional background information on the website of the Sasha Mendjan group at the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA).